Please login to the form below

tenofovir alafenamide

This page shows the latest tenofovir alafenamide news and features for those working in and with pharma, biotech and healthcare.

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.

Gilead builds case for Descovy PrEP after FDA approval

Descovy (emtricitabine/tenofovir alafenamide) claimed its FDA approval for PrEP last week – becoming only the second drug for this use since Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) got a green
J&J pledges $500m investment into HIV and tuberculosis R&D

and tenofovir alafenamide) was recently approved by the FDA.
Gilead claims FDA okay for Descovy as second PrEP option

Descovy (emtricitabine and tenofovir alafenamide) has been cleared for adolescents and adults who are at risk of HIV infection because they have sex with an HIV-positive partner. ... In a statement, the FDA said that Descovy’s efficacy in preventing
ViiV builds case for switching to its two-drug HIV combinations

48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing
ViiV bags EU okay for new two-drug HIV therapy

bictegravir/emtricitabine/tenofovir alafenamide) product.

More from news
Approximately 4 fully matching, plus 41 partially matching documents found.

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Add my company

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...